It is well known that PX-478 and EZN-2968 are dose-dependent drugs that reduce the secretion of HIF-1α and VEGF and cause tumor shrinkage in xenograft animal models, and that satisfactory results were obtained in phase I clinical trials.154. This evidence concerns the gene HIF1A and neoplasm.